Allan Rodriguez

VitaDX develops software solutions to detect cancer using image processing and artificial intelligence. For more information check out our website: www.vitadx.com Follow us on twitter @VitaDX_SA

Startsquare is a meeting place between tech projects, entrepreneurs and innovative companies. Looking for tech opportunities ? Become a ‘Project Adopter’ and get access to techs from academic research, licensing programs, open innovation or emerging startups. They all need help to go further. You have tech projects you want to promote? Join ‘Project Providers’ on the platform and find co-founders or B2B partners among Startsquare’s dynamic community Created in 2015 in Lyon.

CeleScreen develops an innovative technology for the rapid screening of xenobiotics toxicity by means of Caenorhabditis elegans, a <1mm nematode, long-known model for human metabolism. It is a unique solution for systemic toxicity, reprotoxicity, teratogenicity, while avoiding vertebrate testing. Primary targets are in the cosmetics industry to face REACH demands. Celescreen has recently launched collaborative projects incorporating C. elegans and in silico approaches for drug development in human health. Incorporated in 2015, based at Hôpital Lariboisière in Paris, CeleScreen is a licensee of Assistance Publique - Hôpitaux de Paris (AP-HP), a major player in human health with >20,000 medical doctors.

VitaDX develops software solutions to detect cancer using image processing and artificial intelligence. For more information check out our website: www.vitadx.com Follow us on twitter @VitaDX_SA

Supporting public and private companies in the setting up of national and European H2020 individual (SME Instrument Phases 1&2) but also collaborative (IA, RIA FTI and Eurostars) innovation projects. Our goal is your success and we are committed to sharing with you all the expertise in order to assist you in the optimisation of your research and innovation projects. Together we can turn your ideas into winning projects! You can also find us on Facebook: https://www.facebook.com/novanexia/ Twitter: https://twitter.com/novanexia Have a closer look and contact us with any questions or inquiries.

Startsquare is a meeting place between tech projects, entrepreneurs and innovative companies. Looking for tech opportunities ? Become a ‘Project Adopter’ and get access to techs from academic research, licensing programs, open innovation or emerging startups. They all need help to go further. You have tech projects you want to promote? Join ‘Project Providers’ on the platform and find co-founders or B2B partners among Startsquare’s dynamic community Created in 2015 in Lyon.

CeleScreen develops an innovative technology for the rapid screening of xenobiotics toxicity by means of Caenorhabditis elegans, a <1mm nematode, long-known model for human metabolism. It is a unique solution for systemic toxicity, reprotoxicity, teratogenicity, while avoiding vertebrate testing. Primary targets are in the cosmetics industry to face REACH demands. Celescreen has recently launched collaborative projects incorporating C. elegans and in silico approaches for drug development in human health. Incorporated in 2015, based at Hôpital Lariboisière in Paris, CeleScreen is a licensee of Assistance Publique - Hôpitaux de Paris (AP-HP), a major player in human health with >20,000 medical doctors.